Ciechanover Isaac E. 4
4 · Atara Biotherapeutics, Inc. · Filed Mar 18, 2019
Insider Transaction Report
Form 4
Ciechanover Isaac E.
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2019-03-15$38.73/sh−3,900$151,047→ 327,737 total(indirect: See footnote) - Sale
Common Stock
2019-03-14$39.10/sh−700$27,370→ 334,837 total(indirect: See footnote) - Sale
Common Stock
2019-03-14$40.48/sh−3,200$129,536→ 331,637 total(indirect: See footnote)
Holdings
- 332,243
Common Stock
Footnotes (5)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.92 to $39.39. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- [F4]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.02 to $40.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.15 to $39.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.